gout and tirzepatide uric acid risk change in and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised Gout and Diet

In the UK, NICE technology appraisals (TA875 for semaglutide and TA664 for liraglutide) specify that these treatments should be prescribed within specialist weight management services, with continuation dependent on achieving at least 5% weight loss at specified timepoints

Contextualize heart rate changes within the broader cardiovascular picture

Incorporating semaglutide into a well-rounded weight management program is the best way to get the results that you're after from this drug

SheMed is monitoring its development closely and will update guidance as the regulatory picture becomes clearer

The TUE burden would be enormous